Epidermal growth factor receptor inhibitor therapy for recurrent respiratory papillomatosis

James D Sidman, Matthew M. Moldan, Bruce C. Bostrom, Robert J. Tibesar, Timothy A. Lander

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


The epidermal growth factor pathway has been implicated in various tumors, including human papillomavirus (HPV) lesions such as recurrent respiratory papillomatosis (RRP). Due to the presence of epidermal growth factor receptors in RRP, epidermal growth factor receptor (EGFR) inhibitors have been utilized as adjuvant therapy. This case series examines the response to EGFR inhibitors in RRP. Four patients with life-threatening RRP were treated with EGFR inhibitors. Operative frequency and anatomical Derkay scores were calculated prior to, and following EGFR inhibitor treatment via retrospective chart review. The anatomical Derkay score decreased for all four patients after initiation of EGFR inhibitor therapy. In one patient, the operative frequency increased after switching to an intravenous inhibitor after loss of control with an oral inhibitor. In the other patients there was a greater than 20% decrease in operative frequency in one and a more than doubling in the time between procedures in two. This study suggests that EGFR inhibitors are a potential adjuvant therapy in RRP and deserve further study in a larger number of patients.

Original languageEnglish (US)
Article number2-202.v1
StatePublished - Oct 3 2013

Bibliographical note

Publisher Copyright:
© 2013 Moldan MM et al.


Dive into the research topics of 'Epidermal growth factor receptor inhibitor therapy for recurrent respiratory papillomatosis'. Together they form a unique fingerprint.

Cite this